Analysis of:
Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal (online.wsj.com)
It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.
Analysis of:
Higher Risks Found for Anemia Drugs (online.wsj.com)
Meta analysis of multiple papers shows an increased risk of dealth in cancer patients receiving Epo products.
Analysis of:
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib (bloodjournal.hematologylibrary.org)
IF this agent works it is ORAL and will certainly be more acceptable to patients than the IV Velcade.
Analysis of:
Study: More Complexity In Tailoring Cancer Drugs (online.wsj.com)
Roche Holding may well be leading the way to make gene analysis more cost effective and individualize cancer care by targeting the mutations!!
Analysis of:
Vaccinating Boys for Girls’ Sake? (www.nytimes.com)
Merck's HPV vaccine, Gardasil is expected to be approved for boys to extend "herd immunity" and offer more prevention to girls from cervical cancer. This " altruistic" goal comes with benefits for boys: eradication of 90 % of genital warts cases, and possible long term prevention of anal , penile, and...
Analysis of:
Genentech Clears Hurdle On Cancer Drug Avastin (online.wsj.com)
As expected, FDA gave accelerated approval for Genetech's Avastin in metastatic breast cancer, thus requiring Genentech to do further studies to show survival benefit and confirm the PFS survival. This decision will "officially" introduces Avastin to breast cancer market, where use has been already...
Analysis of:
Vaccinating Boys for Girls’ Sake? (www.nytimes.com)
Merck intends to market this viral vaccine to "protect" women from the risk of cervical carcinoma.
Analysis of:
Genentech Clears Hurdle On Cancer Drug Avastin (online.wsj.com)
Avastin will be used in the therapy of "advanced" metastatic breast cancer, despite controversial data. In a disease with multiple options and a variable course it is virtually impossible to prove improved survival!!
Analysis of:
Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE(TM) in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer (www.pipelinereview.com)
1) This article is a bit confusing as in the beginning it refers to hormone sensitive disease,when in fact,later in the text,it is the HRPC(hormone refracory prostate cancer) cells that are targetted.
2)That being said,the mechanism of action and animal data look interesting and certainly worth pursuing...
Analysis of:
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma (www.pipelinereview.com)
Cephalon's Treanda have shown efficacy in relapsed/refractory indolent NHL and also in CLL, and is expected to get FDA approval for both indications. Cephalon currently has FDA approval for Trisenox for relapsed APL ( a less common form of AML) and is developing Lasteurinib for FLT-3 positive...